Comparative Pharmacology
Head-to-head clinical analysis: A P L versus OVIDREL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: A P L versus OVIDREL.
A.P.L. vs OVIDREL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
A.P.L. (Chorionic Gonadotropin) acts as a luteinizing hormone (LH) agonist, binding to LH receptors in the gonads to stimulate testosterone production in males and ovulation in females.
OVIDREL (choriogonadotropin alfa) acts as a luteinizing hormone (LH) agonist, binding to the LH/choriogonadotropin receptor on ovarian theca and granulosa cells, triggering ovulation and luteinization by inducing resumption of oocyte meiosis and follicle rupture.
500-1000 mg every 4-6 hours, not to exceed 3000 mg/day in adults.
250 mcg subcutaneously once daily for 7 days following recombinant FSH stimulation. Alternatively, a single 250 mcg subcutaneous dose is used to trigger final follicular maturation 24-48 hours after last gonadotropin dose.
None Documented
None Documented
Terminal elimination half-life: 2.5–3.5 hours (elimination phase); clinical context: requires repeated dosing for sustained effect.
The terminal elimination half-life is approximately 30 hours (range 20-48 hours) in healthy adults. This supports a single-dose regimen for final follicular maturation in assisted reproductive technology.
Renal: 10% unchanged; hepatic metabolism to inactive metabolites excreted in urine and feces (90% combined).
Primarily renal, with approximately 10% of the administered dose excreted unchanged in urine within 24 hours. The remainder undergoes metabolic degradation in the kidneys and liver.
Category C
Category C
Gonadotropin
Gonadotropin